Our Science
Explore the science behind our innovative Degrader-Antibody Conjugate (DAC) platform and the future of targeted protein degradation.
Targeted Protein Degradation: The Next Frontier in Therapeutics
For too long, drug discovery has been constrained by the "undruggable"—disease-causing proteins that lack traditional binding pockets for small molecule inhibitors. TPD offers a paradigm shift, harnessing the cell's own natural machinery to selectively eliminate disease-causing proteins rather than merely inhibiting their function. Unlike conventional inhibitors that require continuous high-dose exposure to maintain efficacy, a single molecule in TPD can catalyze the degradation of multiple target proteins, offering more durable and transformative therapeutic effects.
Degrader-Antibody Conjugates: Precision Delivery for Universal Adoption
While TPD holds immense promise, traditional degraders face challenges. Our innovative Degrader-Antibody Conjugate (DAC) platform delivers the definitive solution. DACs combine the precision of monoclonal antibodies with the potent catalytic power of protein degraders. This enables highly specific delivery of degrader payloads directly to target cells, overcoming systemic limitations, improving the therapeutic index, and minimizing off-target toxicity. The TriCore platform's modular approach allows for broad applicability across a wide range of targets and disease areas.
